Skip to Content

New Drug Approvals Archive - March 2004

March 2004

Iquix (levofloxacin ophthalmic) Ophthalmic Solution

Date of Approval: March 1, 2004
Company: Santen
Treatment for: Corneal Ulcers

Iquix (levofloxacin) is a topical fluoroquinolone indicated for the treatment of bacterial corneal ulcers.

Read more: Iquix (levofloxacin ophthalmic) FDA Approval History

Sensipar (cinacalcet) Tablets

Date of Approval: March 8, 2004
Company: Amgen Inc.
Treatment for: Secondary Hyperparathyroidism, Hypercalcemia of Malignancy

Sensipar (cinacalcet) is a calcimimetic agent indicated for the treatment of secondary hyperparathyroidism in dialysis patients and for the treatment of hypercalcemia in patients with parathyroid carcinoma.

Read more: Sensipar (cinacalcet) FDA Approval History

Follistim AQ (follitropin beta) Injection

Date of Approval: March 24, 2004
Company: Organon USA Inc.
Treatment for: Female Infertility, Hypogonadism -- Male, Ovulation Induction

Follistim AQ (follitropin beta) is human follicle-stimulating hormone prescribed for women undergoing assisted reproductive treatments (ART) such as in vitro fertilization (IVF), and for the induction of ovulation to achieve pregnancy, and for men with hypogonadism.

Read more: Follistim AQ (follitropin beta) FDA Approval History

New Drug Approvals Archive